KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 3 filers reported holding KALA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $4,000 | -96.3% | 16,733 | -78.6% | 0.00% | -100.0% |
| Q1 2022 | $108,000 | -9.2% | 78,099 | -20.4% | 0.00% | -33.3% |
| Q4 2021 | $119,000 | -62.3% | 98,130 | -18.7% | 0.00% | -50.0% |
| Q3 2021 | $316,000 | +109.3% | 120,678 | +324.7% | 0.01% | +100.0% |
| Q2 2021 | $151,000 | -12.7% | 28,418 | +72.2% | 0.00% | -62.5% |
| Q2 2020 | $173,000 | – | 16,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |